相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis
Omar Abdel-Rahman et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis
Omar Abdel-Rahman et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
M. Dror Michaelson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)
H. J. M. Groen et al.
ANNALS OF ONCOLOGY (2013)
Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer
John P. Crown et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside
Omar Abdel-Rahman
JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE (2013)
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study
A. Poprach et al.
ANNALS OF ONCOLOGY (2012)
Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2012)
Polymorphisms to Predict Outcome to the Tyrosine Kinase Inhibitors Gefitinib, Erlotinib, Sorafenib and Sunitinib
Lale Erdem et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2012)
First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
Jonas Bergh et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
Giorgio V. Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Chemotherapy and skin reactions
Gabriella Fabbrocini et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2012)
Sunitinib for the treatment of metastatic renal cell carcinoma
Stephane Oudard et al.
CANCER TREATMENT REVIEWS (2011)
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
Sylvie Negrier et al.
LANCET ONCOLOGY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer
H. Wildiers et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
Carlos H. Barrios et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Safety and Efficacy of Combining Sunitinib with Bevacizumab plus Paclitaxel/Carboplatin in Non-small Cell Lung Cancer
Mark A. Socinski et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non-Renal Cell Carcinoma: A Meta-analysis
David Chu et al.
CLINICAL GENITOURINARY CANCER (2009)
Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma
H. Huynh et al.
CURRENT CANCER DRUG TARGETS (2009)
Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer
Nathalie Theou-Anton et al.
DRUG SAFETY (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Martin E. Gore et al.
LANCET ONCOLOGY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice
H Yoshiji et al.
HEPATOLOGY (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
分享论文
